Literature DB >> 20164685

What is the difference between triple-negative and basal breast cancers?

Melanie D Seal1, Stephen K Chia.   

Abstract

Triple-negative breast cancer (TNBC) represents a phenotype defined by the lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression. Because TNBCs have more aggressive features and lack a therapeutic target, they have become a key topic of clinical and research interest within the oncology community. With advancements in the field of molecular biology, gene expression profiling has resulted in the identification of intrinsic subtypes including basal-like breast cancers (BLBCs). Although often thought to be synonymous, TNBC and BLBC represent different biologic phenomena. Furthermore, even within the basal-like subtype, diversity exists. The purpose of this review is to outline the most current evidence in an attempt to answer the question: what is BLBC?

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164685     DOI: 10.1097/PPO.0b013e3181cf04be

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

1.  Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.

Authors:  Yong Weon Yi; Hyo Jin Kang; Hee Jeong Kim; Jae Seok Hwang; Antai Wang; Insoo Bae
Journal:  Mol Carcinog       Date:  2012-04-04       Impact factor: 4.784

2.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

3.  Environmental cadmium and breast cancer risk.

Authors:  Carolyn M Gallagher; John J Chen; John S Kovach
Journal:  Aging (Albany NY)       Date:  2010-11       Impact factor: 5.682

Review 4.  Gene signatures of breast cancer progression and metastasis.

Authors:  David I Rodenhiser; Joseph D Andrews; Theodore A Vandenberg; Ann F Chambers
Journal:  Breast Cancer Res       Date:  2011-01-24       Impact factor: 6.466

5.  A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.

Authors:  Punit Kaur; Ganachari M Nagaraja; Hongying Zheng; Dawit Gizachew; Moses Galukande; Sunil Krishnan; Alexzander Asea
Journal:  BMC Cancer       Date:  2012-03-27       Impact factor: 4.430

6.  Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.

Authors:  Young Hwa Soung; Kevin Pruitt; Jun Chung
Journal:  Sci Rep       Date:  2014-01-24       Impact factor: 4.379

7.  Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.

Authors:  Yong Weon Yi; Wooyoung Hong; Hyo Jin Kang; Hee Jeong Kim; Wenjing Zhao; Antai Wang; Yeon-Sun Seong; Insoo Bae
Journal:  J Cell Mol Med       Date:  2013-04-20       Impact factor: 5.310

8.  Reinventing diagnostics for personalized therapy in oncology.

Authors:  Diponkar Banerjee
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

9.  Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging.

Authors:  Wen Jiang; Yeming Han; Ting Liang; Chao Zhang; Feng Gao; Guihua Hou
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

10.  Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.

Authors:  Marie-Anne Goyette; Islam E Elkholi; Chloé Apcher; Hellen Kuasne; Carla V Rothlin; William J Muller; Darren E Richard; Morag Park; Jean-Philippe Gratton; Jean-François Côté
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.